Amanda Sheppeard

Respiratory specialists want pharmaceutical companies to come clean about tobacco and vaping industry interests behind taxpayer-funded medicines.

A long-acting biologic for severe eosinophilic asthma is among the respiratory-relevant medicines backed for PBS subsidy at the July PBAC meeting.

Australian real-world data show vaccination during pregnancy provides strong protection against RSV hospitalisation, particularly during babies' first months of life.

An Australian immunologist is developing a blood test that could help identify patients at risk of severe respiratory disease from the moment they arrive in hospital.

The peak body's new white paper calls for PBS pricing reform, earlier shortage detection, and streamlined regulation to strengthen Australia's medicine supply resilience.

Plasma cell leukaemia should no longer be considered a separate cancer but instead be classified as a subtype of high-risk multiple myeloma, say two international myeloma experts.

New and expanded PBS listings across blood and lung cancers were among the oncology wins from the July PBAC meeting, while a breast cancer drug was knocked back again.

The drug maker behind experimental obesity treatment retatrutide has stepped up its attack on a growing black market for the unapproved peptide, as Australian authorities warn of serious toxicity linked to products being sold online.

Simply increasing Medicare rebates could pour more public money into specialist care without cutting patients' out-of-pocket costs, a new report warns.

The US regulator's approval of the first-in-class RAS inhibitor daraxonrasib has fuelled calls for access in Australia.